| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| DGA1 | ELO1 | YOR245C | YJL196C | Diacylglycerol O-acyltransferase 1; Diacylglycerol acyltransferase; catalyzes the terminal step of triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor; Lro1p and Dga1p can O-acylate ceramides; localized to lipid particles. | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | 0.508 |
| DGA1 | ELO2 | YOR245C | YCR034W | Diacylglycerol O-acyltransferase 1; Diacylglycerol acyltransferase; catalyzes the terminal step of triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor; Lro1p and Dga1p can O-acylate ceramides; localized to lipid particles. | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | 0.437 |
| DGA1 | MGA2 | YOR245C | YIR033W | Diacylglycerol O-acyltransferase 1; Diacylglycerol acyltransferase; catalyzes the terminal step of triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor; Lro1p and Dga1p can O-acylate ceramides; localized to lipid particles. | ER membrane protein involved in regulation of OLE1 transcription; inactive ER form dimerizes and one subunit is then activated by ubiquitin/proteasome-dependent processing followed by nuclear targeting; MGA2 has a paralog, SPT23, that arose from the whole genome duplication. | 0.433 |
| DGA1 | OLE1 | YOR245C | YGL055W | Diacylglycerol O-acyltransferase 1; Diacylglycerol acyltransferase; catalyzes the terminal step of triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor; Lro1p and Dga1p can O-acylate ceramides; localized to lipid particles. | Acyl-CoA desaturase 1; Delta(9) fatty acid desaturase; required for monounsaturated fatty acid synthesis and for normal distribution of mitochondria. | 0.964 |
| ECM16 | ERG25 | YMR128W | YGR060W | Essential DEAH-box ATP-dependent RNA helicase specific to U3 snoRNP; predominantly nucleolar in distribution; required for 18S rRNA synthesis. | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | 0.947 |
| ECM16 | OLE1 | YMR128W | YGL055W | Essential DEAH-box ATP-dependent RNA helicase specific to U3 snoRNP; predominantly nucleolar in distribution; required for 18S rRNA synthesis. | Acyl-CoA desaturase 1; Delta(9) fatty acid desaturase; required for monounsaturated fatty acid synthesis and for normal distribution of mitochondria. | 0.948 |
| ELO1 | DGA1 | YJL196C | YOR245C | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | Diacylglycerol O-acyltransferase 1; Diacylglycerol acyltransferase; catalyzes the terminal step of triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor; Lro1p and Dga1p can O-acylate ceramides; localized to lipid particles. | 0.508 |
| ELO1 | ELO2 | YJL196C | YCR034W | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | 0.999 |
| ELO1 | ELO3 | YJL196C | YLR372W | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | Elongation of fatty acids protein 3; Elongase; involved in fatty acid and sphingolipid biosynthesis; synthesizes very long chain 20-26-carbon fatty acids from C18-CoA primers; involved in regulation of sphingolipid biosynthesis; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7; Belongs to the ELO family. | 0.918 |
| ELO1 | IFA38 | YJL196C | YBR159W | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | Very-long-chain 3-oxoacyl-CoA reductase; Microsomal beta-keto-reductase; contains oleate response element (ORE) sequence in the promoter region; mutants exhibit reduced VLCFA synthesis, accumulate high levels of dihydrosphingosine, phytosphingosine and medium-chain ceramides; Belongs to the short-chain dehydrogenases/reductases (SDR) family. | 0.983 |
| ELO1 | OLE1 | YJL196C | YGL055W | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | Acyl-CoA desaturase 1; Delta(9) fatty acid desaturase; required for monounsaturated fatty acid synthesis and for normal distribution of mitochondria. | 0.995 |
| ELO1 | TSC13 | YJL196C | YDL015C | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | Very-long-chain enoyl-CoA reductase; Enoyl reductase; catalyzes last step in each cycle of very long chain fatty acid elongation; localizes to ER, highly enriched in a structure marking nuclear-vacuolar junctions; coimmunoprecipitates with elongases Elo2p and Elo3p; protein increases in abundance and relative distribution to ER foci increases upon DNA replication stress; human homolog TECR implicated in nonsyndromic mental retardation, can complement yeast mutant; Belongs to the steroid 5-alpha reductase family. | 0.968 |
| ELO2 | DGA1 | YCR034W | YOR245C | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | Diacylglycerol O-acyltransferase 1; Diacylglycerol acyltransferase; catalyzes the terminal step of triacylglycerol (TAG) formation, acylates diacylglycerol using acyl-CoA as an acyl donor; Lro1p and Dga1p can O-acylate ceramides; localized to lipid particles. | 0.437 |
| ELO2 | ELO1 | YCR034W | YJL196C | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | 0.999 |
| ELO2 | ELO3 | YCR034W | YLR372W | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | Elongation of fatty acids protein 3; Elongase; involved in fatty acid and sphingolipid biosynthesis; synthesizes very long chain 20-26-carbon fatty acids from C18-CoA primers; involved in regulation of sphingolipid biosynthesis; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7; Belongs to the ELO family. | 0.999 |
| ELO2 | IFA38 | YCR034W | YBR159W | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | Very-long-chain 3-oxoacyl-CoA reductase; Microsomal beta-keto-reductase; contains oleate response element (ORE) sequence in the promoter region; mutants exhibit reduced VLCFA synthesis, accumulate high levels of dihydrosphingosine, phytosphingosine and medium-chain ceramides; Belongs to the short-chain dehydrogenases/reductases (SDR) family. | 0.988 |
| ELO2 | OLE1 | YCR034W | YGL055W | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | Acyl-CoA desaturase 1; Delta(9) fatty acid desaturase; required for monounsaturated fatty acid synthesis and for normal distribution of mitochondria. | 0.989 |
| ELO2 | TSC13 | YCR034W | YDL015C | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | Very-long-chain enoyl-CoA reductase; Enoyl reductase; catalyzes last step in each cycle of very long chain fatty acid elongation; localizes to ER, highly enriched in a structure marking nuclear-vacuolar junctions; coimmunoprecipitates with elongases Elo2p and Elo3p; protein increases in abundance and relative distribution to ER foci increases upon DNA replication stress; human homolog TECR implicated in nonsyndromic mental retardation, can complement yeast mutant; Belongs to the steroid 5-alpha reductase family. | 0.989 |
| ELO3 | ELO1 | YLR372W | YJL196C | Elongation of fatty acids protein 3; Elongase; involved in fatty acid and sphingolipid biosynthesis; synthesizes very long chain 20-26-carbon fatty acids from C18-CoA primers; involved in regulation of sphingolipid biosynthesis; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7; Belongs to the ELO family. | Elongation of fatty acids protein 1; Elongase I, medium-chain acyl elongase; catalyzes carboxy-terminal elongation of unsaturated C12-C16 fatty acyl-CoAs to C16-C18 fatty acids; ELO1 has a paralog, ELO2, that arose from the whole genome duplication. | 0.918 |
| ELO3 | ELO2 | YLR372W | YCR034W | Elongation of fatty acids protein 3; Elongase; involved in fatty acid and sphingolipid biosynthesis; synthesizes very long chain 20-26-carbon fatty acids from C18-CoA primers; involved in regulation of sphingolipid biosynthesis; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7; Belongs to the ELO family. | Elongation of fatty acids protein 2; Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty acids of up to 24 carbons in length; mutations have regulatory effects on 1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway; ELO2 has a paralog, ELO1, that arose from the whole genome duplication; lethality of the elo2 elo3 double null mutation is functionally complemented by human ELOVL1 and weakly complemented by human ELOVL3 or ELOV7. | 0.999 |